Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$12.02 - $21.3 $344,974 - $611,310
-28,700 Reduced 56.45%
22,138 $462,000
Q1 2024

May 15, 2024

BUY
$7.77 - $15.66 $14,141 - $28,501
1,820 Added 3.71%
50,838 $747,000
Q4 2023

Feb 15, 2024

BUY
$4.25 - $10.71 $54,740 - $137,944
12,880 Added 35.64%
49,018 $505,000
Q3 2023

Dec 19, 2023

SELL
$7.86 - $10.08 $391,805 - $502,467
-49,848 Reduced 57.97%
36,138 $284,000
Q3 2023

Nov 15, 2023

SELL
$7.86 - $10.08 $391,805 - $502,467
-49,848 Reduced 57.97%
36,138 $284,000
Q2 2023

Dec 19, 2023

SELL
$8.7 - $13.28 $47,789 - $72,947
-5,493 Reduced 6.0%
85,986 $859,000
Q2 2023

Aug 15, 2023

SELL
$8.7 - $13.28 $47,789 - $72,947
-5,493 Reduced 6.0%
85,986 $859,000
Q1 2023

Dec 19, 2023

BUY
$8.56 - $13.26 $66,459 - $102,950
7,764 Added 9.27%
91,479 $812,000
Q1 2023

May 15, 2023

BUY
$8.56 - $13.26 $66,459 - $102,950
7,764 Added 9.27%
91,479 $812,000
Q4 2022

Dec 19, 2023

BUY
$9.86 - $14.59 $469,109 - $694,148
47,577 Added 131.65%
83,715 $919,000
Q4 2022

Feb 15, 2023

BUY
$9.86 - $14.59 $88,503 - $130,959
8,976 Added 12.01%
83,715 $919,000
Q3 2022

Nov 15, 2022

BUY
$12.33 - $19.81 $198,352 - $318,683
16,087 Added 27.43%
74,739 $974,000
Q2 2022

Aug 15, 2022

BUY
$7.88 - $14.82 $123,692 - $232,629
15,697 Added 36.54%
58,652 $743,000
Q1 2022

May 16, 2022

BUY
$12.94 - $29.65 $183,282 - $419,962
14,164 Added 49.2%
42,955 $602,000
Q1 2021

May 14, 2021

BUY
$26.98 - $50.17 $776,781 - $1.44 Million
28,791 New
28,791 $895,000

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $923M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Public Employees Retirement System Of Ohio Portfolio

Follow Public Employees Retirement System Of Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Public Employees Retirement System Of Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Public Employees Retirement System Of Ohio with notifications on news.